Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?

BMC Nephrology

Volumn 7, Issue , 2006, Pages

  Gabutti, Luca ^a   Lötscher, Nathalie ^b   Bianda, Josephine ^a   Marone, Claudio ^c   Mombelli, Giorgio ^a   Burnier, Michel ^d  

^a Ospedale La Carita   (Switzerland)

^b Roche Pharma Schweiz AG   (Switzerland)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; ARTIFICIAL NEURAL NETWORK; CONTROLLED STUDY; DIALYSIS; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROLOGIST; PERFORMANCE; PREDICTION; SENSITIVITY AND SPECIFICITY; SWITZERLAND; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COMPUTER SIMULATION; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG THERAPY, COMPUTER-ASSISTED; ERYTHROPOIETIN; EXPERT SYSTEMS; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEPHROLOGY; NEURAL NETWORKS (COMPUTER); POINT-OF-CARE SYSTEMS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SWITZERLAND; TREATMENT OUTCOME;

EID: 33749146120     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-7-13     Document Type: Article

References (44)

1. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2001, 37:S182-238.
2. Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988, 34:525-528.
3. Bàràny P, Petterson E, Konarski-Svensson JK: Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 1993, 8:426-432.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of Anemia on Cardiomyopathy, Morbidity, and Mortality in End-Stage Renal Disease. Am J Kidney Dis 1996, 28:53-61.
5. Locatelli F, Aljama P, Bàràny P, Canaud B, Carrera F, Eckhardt KU, Hörl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004, 19 Suppl 2:ii1-47.
6. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fare J: Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004, 10:225-232.
7. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM: The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004, 27:185-190.
8. Douglas SW, Adamson JW: The anemia of chronic disorders; studies of marrow regulations and iron metabolism. Blood 1975, 45:55-65.
9. Koch KM, Patyna D, Shaldon S, Werner E: Anemia of the regular hemodialysis, patient and its treatment. Nephron 1974, 12:405-419.
10. Ifudu O, Feldmann J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with endstage renal disease. N Engl J Med 1996, 334:420-425.
11. Besarab A, Amin N, Ahsan M: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000, 11:530-538.
12. Whitehead VM, Compty CH, Posen GA, Kaye M: Homeostasis of folic acid in patients undergoing maintenance hemodialysis. N Engl J Med 1968, 279:970-974.
13. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993, 328:171-175.
14. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE: The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 1991, 6:342-345.
15. Krantz SB: Pathogenesis and treatment of anemia of chronic disease. Am J Med Sci 1994, 307:353-359.
16. Onoyama K, Sanai T, Motomura K, Fujishima M: Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989, 13 Suppl 3:S27-30.
17. Ikeda Y, Sakemi T, Ohtsuka Y: Drug-related low responsivness to recombinant human erythropoetin therapy in three patients with end-stage renal disease. Nephrol Dial Transplant 1997, 12:371-372.
18. Aiello J: Anemia management protocols and epoetin alfa administration: an algorithm approach. Nephrol Nurs J 2002, 29:297-300.
19. Martin-Guerrero JD, Camps-Valls G, Soria-Olivas E, Serrano-Lopez AJ, Perez-Ruixo JJ, Jimenez-Torres NV: Dosage individualisation of erythropoietin using a profile-dependent support vector regression. IEEE Trans Biomed Eng 2003, 50:1136-1142.
20. Martin-Guerrero JD, Soria-Olivas E, Camps-Valls G, Serrano-Lopez AJ, Perez-Ruixo JJ, Jimenez-Torres NV: Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure. Comput Biol Med 2003, 33:361-373.
21. Richardson D, Bartlett C, Will EJ: Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 2001, 38:109-117.
22. Richardson D, Bartlett C, Will EJ: Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 2000, 15:2007-2013.
23. Bellazzi R, Siviero C, Bellazzi R: Mathematical modeling of erythropoietin therapy in uremic anemia. Does it improve cost-effectiveness? Haematologica 1994, 79:154-164.
24. Bellazzi R: Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia. Comput Biomed Res 1993, 26:274-293.
25. Gaweda AE, Jacobs AA, Brier ME, Zurada JM: Pharmacodynamic population analysis in chronic renal failure using artificial neural networks: a comparative study. Neural Netw 2003, 16:841-845.
26. Jacobs AA, Lada P, Zurada JM, Brier ME, Aronoff GR: Predictors of hematocrit in hemodialysis patients as determined by artificial neural networks. J Am Soc Nephrol 2001, 12:387A.
27. Gabutti L, Machacek M, Marone C, Ferrari P: Predicting intradialytic hypotension from experience, statistical models and artificial neural networks. J Nephrol 2005, 18:409-416.
28. Gabutti L, Burnier M, Mombelli G, Malé F, Pellegrini L, Marone C: Usefulness of artificial neural networks to predict follow-up dietary protein intake in hemodialysis patients. Kidney Int 2004, 66:399-407.
29. Gabutti L, Vadilonga D, Mombelli G, Burnier M, Marone C: Artificial neural networks. improve the prediction of Kt/V, follow-up dietary protein intake and hypotension risk in hemodialysis patients. Nephrol Dial Transplant 2004, 19:1204-1211.
30. Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, Gomis P, Barbaut X, Tahani B: Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control. Ther Drug Monit 1993, 15:380-393.
31. Reggia JA: Neural computation in medicine. Artif Intell Med 1993, 5:143-157.
32. Kohonen T: An introduction to neural computing. Neural Netw 1988, 1:3-16.
33. Cross SS, Harrison RF, Kennedy RL: Introduction to neural networks. Lancet 1995, 346:1075-1079.
34. Markey MK, Tourassi GD, Margolis M, Delong DM: Impact of missing data in evaluating artificial neural networks trained on complete data. Comput Biol Med 2006, 36:516-525.
35. Ennett CM, Frize M, Walker CR: Influence of missing values on artificial neural network performance. Medinfo 2001, 10:449-453.
36. Almeida JS: Predictive non-linear modeling of complex data by artificial neural networks. Curr Opin Biotechnol 2002, 13:72-76.
37. Tu JV: Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. J Clin Epidemiol 1996, 49:1225-1231.
38. Forsstrom JJ, Dalton KJ: Artificial neural networks for decision support in clinical medicine. Ann Med 1995, 27:509-517.
39. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993, 4:1205.
40. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
41. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002, 40:439-446.
42. Bleuel H, Hoffmann R, Kaumann B, Neubert P, Ochlich PP, Schaumann W: Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology 1996, 52:329-338.
43. Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O: Recombinant Human Erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. Clin Pharmacokinet 2004, 43:57-70.
44. Sheiner LB, Beal S, Rosenberg B, Marathe VV: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979, 26:294-305.